I did not perform Fragmentation for my 1st FFPE sample. Now I am thinking I may need do to do that to narrow the insert size ...
Unconfigured Ad
Collapse
X
-
RNA size range as yours - but with a sligthly higher peak ~200 nt. How do you purify the library after amplification? Using MiniElute will give you some "primer-dimer" contamination. We are using AMPure XP but you may need to play around with the bead ratio to get rid of the "primer-dimer" without removing too much of the library. Have you considered gel purification?Originally posted by HedleyC View PostJakob, I have been involved in a piece of work trying to do the same thing - but we just got massive adapter contamination in the final data. What size range was your FFPE RNA peak after RiboZero GOLD but before the ScriptSeq? Ours was between 25-500bp approximately, peak generally around 100.
Regards,
Hedley
/Jakob
Comment
-
-
Hi Jakob,Originally posted by JakobHedegaard View PostRNA size range as yours - but with a sligthly higher peak ~200 nt. How do you purify the library after amplification? Using MiniElute will give you some "primer-dimer" contamination. We are using AMPure XP but you may need to play around with the bead ratio to get rid of the "primer-dimer" without removing too much of the library. Have you considered gel purification?
/Jakob
The ScriptSeq and later steps were performed by a 3rd party. They used AMPure XP, but it's unclear if they used the right bead ratio to minimise carry-through of the adapter dimers (I suspect not). We are doing some repeat work and also looking at another FFPE kit, so if I find out anything useful, will post it here at some point.
/Hedley
Comment
-
-
@ServiceXS, we obtained enough (>500 ng total RNA) purifiying from 2-3 sections from a FPFE block. For Ribo-Zero we started with 500 ng total RNA but have prepared libraries with 100 ng RNA - but with more variation in quality and yield.
@woodydon, using Ribo-Zero will result in a much more complex library than using poly-dA selected RNA. Depending on the sample conditions (tissue, stage, etc.) some transcripts can dominate the profile - and this applies to both poly-dA and Ribo-Zero treated RNA. Analysing data from Ribo-Zero treated RNA, I think the major challenge is the profiling of both mature and pre-spliced transcripts which introduce some kind of bias.
Cheers, /Jakob
Comment
-
-
@ServiceXS, we obtained enough (>500 ng total RNA) purifiying from 2-3 sections from a FPFE block. For Ribo-Zero we started with 500 ng total RNA but have prepared libraries with 100 ng RNA - but with more variation in quality and yield.
@woodydon, using Ribo-Zero will result in a much more complex library than using poly-dA selected RNA. Depending on the sample conditions (tissue, stage, etc.) some transcripts can dominate the profile - and this applies to both poly-dA and Ribo-Zero treated RNA. Analysing data from Ribo-Zero treated RNA, I think the major challenge is the profiling of both mature and pre-spliced transcripts which introduce some kind of bias.
Cheers, /Jakob
Comment
-
Latest Articles
Collapse
-
by mylaserKheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
This guide explains everything you need to know about...-
Channel: Articles
Today, 01:13 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 07-09-2026, 10:04 AM
|
0 responses
15 views
0 reactions
|
Last Post
by SEQadmin2
07-09-2026, 10:04 AM
|
||
|
Started by SEQadmin2, 07-08-2026, 10:08 AM
|
0 responses
10 views
0 reactions
|
Last Post
by SEQadmin2
07-08-2026, 10:08 AM
|
||
|
Started by SEQadmin2, 07-07-2026, 11:05 AM
|
0 responses
22 views
0 reactions
|
Last Post
by SEQadmin2
07-07-2026, 11:05 AM
|
||
|
Started by SEQadmin2, 07-02-2026, 11:08 AM
|
0 responses
31 views
0 reactions
|
Last Post
by SEQadmin2
07-02-2026, 11:08 AM
|
Comment